LTR Pharma Ltd (AU:LTP) — Market Cap & Net Worth
Market Cap & Net Worth: LTR Pharma Ltd (LTP)
LTR Pharma Ltd (AU:LTP) has a market capitalization of $75.89 Million (AU$107.25 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #20360 globally and #677 in its home market, demonstrating a 18.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LTR Pharma Ltd's stock price AU$0.59 by its total outstanding shares 181777585 (181.78 Million). Review LTR Pharma Ltd debt and liabilities to assess the company's total debt and financial obligations.
LTR Pharma Ltd Market Cap History: 2023 to 2026
LTR Pharma Ltd's market capitalization history from 2023 to 2026. Data shows growth from $44.37 Million to $75.89 Million (19.05% CAGR).
LTR Pharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LTR Pharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
44.02x
LTR Pharma Ltd's market cap is 44.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $44.37 Million | $90.00 | -$1.45 Million | 493040.35x | N/A |
| 2024 | $104.18 Million | $49.33K | -$6.95 Million | 2111.93x | N/A |
| 2025 | $92.61 Million | $2.10 Million | -$5.59 Million | 44.02x | N/A |
Competitor Companies of LTP by Market Capitalization
Companies near LTR Pharma Ltd in the global market cap rankings as of June 21, 2026.
Key companies related to LTR Pharma Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
LTR Pharma Ltd Historical Marketcap From 2023 to 2026
Between 2023 and today, LTR Pharma Ltd's market cap moved from $44.37 Million to $ 75.89 Million, with a yearly change of 19.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$75.89 Million | -18.06% |
| 2025 | AU$92.61 Million | -11.11% |
| 2024 | AU$104.18 Million | +134.78% |
| 2023 | AU$44.37 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of LTR Pharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $75.89 Million USD |
| MoneyControl | $75.89 Million USD |
| MarketWatch | $75.89 Million USD |
| marketcap.company | $75.89 Million USD |
| Reuters | $75.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LTR Pharma Ltd
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australi… Read more